Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955786 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Cylene Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00955786 is a Phase 1 study that has completed, run by Cylene Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00955786, a Phase 1 study, has completed, sponsored by Cylene Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.
Interventions
- DRUG CX-3543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955786
The ClinicalTrials.gov registry entry for NCT00955786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cylene Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CX-3543 is the first listed.
NCT00955786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955786 about?
NCT00955786 is a clinical study titled "Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas". This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.
What is the current status of trial NCT00955786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2005-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00955786?
The interventions under investigation include: CX-3543 (DRUG).
Who is sponsoring clinical trial NCT00955786?
This trial is sponsored by Cylene Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.